<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02471014</url>
  </required_header>
  <id_info>
    <org_study_id>IRB201401069</org_study_id>
    <nct_id>NCT02471014</nct_id>
  </id_info>
  <brief_title>Effect of Obesity on Immune Response to Pneumovax 23</brief_title>
  <acronym>ROVE</acronym>
  <official_title>The Effect of Obesity on Immune Responses to Pneumococcal Polysaccharide Vaccine, ROVE Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pneumococcal infections are a leading cause of adult and childhood hospitalization and death.&#xD;
      It has been shown that obese individuals are at higher risk for this bacterial infection. As&#xD;
      a result, investigators will vaccinate obese individuals to see if they are offered the same&#xD;
      level of protection from the vaccine as normal-weight individuals. The vaccine used for this&#xD;
      particular bacterial infection is called Pneumovax 23.&#xD;
&#xD;
      The purpose of this study is to compare how body mass index affects protection that the&#xD;
      vaccine provides against these bacteria.&#xD;
&#xD;
      Primary Hypothesis: Levels of protection from the vaccine are no different in pre- and post-&#xD;
      vaccination in healthy BMI individuals and obese individuals.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Participants: For this study, the investigators will recruit 56 participants separated&#xD;
      into two groups. Group 1 will enroll 23 individuals with a BMI between 22 and 25. Group 2&#xD;
      will enroll 23 obese individuals. Study participants will be between the ages of 18-35 and in&#xD;
      good health.&#xD;
&#xD;
      Pre-Screening: Basic eligibility will first be determined by phone or through a&#xD;
      questionnaire. The investigators will acquire weight and height information to calculate BMI,&#xD;
      as well as ask about any chronic health problems. At the end of the pre-screening, an email&#xD;
      address will be requested in order to email a copy of the consent form for the participant to&#xD;
      review before the first visit, during which the consent form will be reviewed with the&#xD;
      participant and any questions addressed. A cell phone number will also be requested to text&#xD;
      participant reminders the night before their appointments (visit 1 and visit 2). If the&#xD;
      participant declines a reminder text, a reminder phone call will be set-up.&#xD;
&#xD;
      Screening: During the in-person screening, the investigators will ask several questions.&#xD;
      Participants with chronic health problems (significant vascular disease, hepatitis, renal&#xD;
      disease, diabetes, immunodeficiency) will be excluded. Individuals already immunized with&#xD;
      Pneumovax23 or Prevnar (another vaccine that protects against pneumococcal infection) will&#xD;
      also be excluded. A pregnancy test will be given to females to exclude pregnant individuals.&#xD;
      An HbA1C (finger prick to get a drop of blood) will also be performed to exclude participants&#xD;
      with high blood sugar levels. Physical exams will be performed and vitals will be taken on&#xD;
      participants who pass the initial screening to help assess health.&#xD;
&#xD;
      Questionnaires will also be given at the first visit to assess stress, which has been shown&#xD;
      to affect the ability to protect against infection.&#xD;
&#xD;
      Study Visits: All participants will receive a Pneumovax 23 vaccine, questionnaires, physical&#xD;
      exams, and undergo 2 blood draws.&#xD;
&#xD;
      Part of the blood will be sent to a research laboratory for gene analysis. This will help us&#xD;
      determine if certain genetic markers explain individual differences in Pneumovax 23 efficacy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Actual">May 16, 2019</completion_date>
  <primary_completion_date type="Actual">March 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-pneumococcal Antibodies Between the Groups</measure>
    <time_frame>Changes in baseline and up to 6 weeks</time_frame>
    <description>IgG antibody titers specific for each serotype in Pneumovax 23 (i.e. 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F) will be analyzed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>UCLA Loneliness Scale Questionnaire Will be Used to Measure a Difference Between the Groups.</measure>
    <time_frame>Baseline</time_frame>
    <description>The UCLA loneliness scale is a 20-item questionnaire, on a scale of 0-3 for each question. This questionnaire measures subjective feelings of loneliness and social isolation. Final score of 0 reflects no loneliness and 60 reflects the maximum amount of loneliness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceived Stress Scale-10 Questionnaire Will be Used to Measure a Difference Between the Groups.</measure>
    <time_frame>Baseline</time_frame>
    <description>The Perceived Stress Scale-10 is a 10-item questionnaire assessing how stressful participants perceive their lives to be. Each question is assessed on a scale of 0 to 4. Final score of 0 reflects no stress and 40 indicates maximum amount of stress.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interpersonal Support Evaluation List-12 Will be Used to Measure a Difference Between the Groups</measure>
    <time_frame>Baseline</time_frame>
    <description>The Interpersonal Support Evaluation List-12, a 12-item questionnaire that measures perceived social support along 3 dimensions: appraisal support (availability of someone to talk to), belonging support (availability of people to do things with), and tangible support (e.g. material aid). This is measured on a scale of 0 to 36. The greater the number the greater perceived support.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life Orientation Test-Revised Will be Used to Measure a Difference Between the Groups.</measure>
    <time_frame>Baseline</time_frame>
    <description>The Life Orientation Test-Revised, a 10-item scale measuring optimism versus pessimism along a continuous scale; a higher score indicates more optimism. The lowest score is 0 and the highest is 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic Analysis</measure>
    <time_frame>Test to be performed in a research laboratory after Visits are completed</time_frame>
    <description>A small amount of blood will be sent to a research laboratory for an analysis of genetic markers Specifically, we will be analyzing the the stimulator of interferon genes (STING). This will help us determine if this gene, which has been previously thought to contribute to Pneumovax efficacy, helps explain individual differences in immune response.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">50</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Obese Individuals</arm_group_label>
    <description>Participants in this group will receive one 0.5mL Pneumovax23 intramuscular vaccine at baseline, four questionnaires administered at baseline, and one 50mL blood draw at baseline and one 50mL blood draw up to 6 weeks later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Individuals</arm_group_label>
    <description>Participants in this group will receive one 0.5mL Pneumovax23 intramuscular vaccine at baseline, four questionnaires administered at baseline, and one 50mL blood draw at baseline and one 50mL blood draw up to 6 weeks later.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pneumovax 23</intervention_name>
    <description>All participants will receive a single 0.5 mL Pneumovax 23 intramuscular vaccine at baseline.</description>
    <arm_group_label>Normal Individuals</arm_group_label>
    <arm_group_label>Obese Individuals</arm_group_label>
    <other_name>pneumococcal polysaccharide vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood tests</intervention_name>
    <description>All participants will have two 50 milliliter blood draws: at baseline and up to 6 weeks later.</description>
    <arm_group_label>Normal Individuals</arm_group_label>
    <arm_group_label>Obese Individuals</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaires</intervention_name>
    <description>All participants will answer the following questionnaires:&#xD;
UCLA Loneliness Scale Questionnaire will be used to measure a difference between the groups.&#xD;
Perceived Stress Scale-10 Questionnaire will be used to measure a difference between the groups.&#xD;
Interpersonal Support Evaluation List-12 will be used to measure a difference between the groups Life Orientation Test-Revised will be used to measure a difference between the groups.</description>
    <arm_group_label>Normal Individuals</arm_group_label>
    <arm_group_label>Obese Individuals</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Area County Adults residents with a diagnosis of Obesity who are otherwise healthy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Control group&#xD;
&#xD;
          -  aged 18-35&#xD;
&#xD;
          -  BMIs between 22-25kg/m2, Obese group&#xD;
&#xD;
          -  Aged 18 - 35&#xD;
&#xD;
          -  BMIs greater than 30kg/m2, and&#xD;
&#xD;
          -  waist to hip ratio of at least 0.9 in males and at least 0.85 in females&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy: Pregnant, Planning to become pregnant, or Breastfeeding&#xD;
&#xD;
          -  Diabetes mellitus (A1C&gt; 6.5%): Diagnosed with diabetes&#xD;
&#xD;
          -  Abnormal CMP and CBC values as determined by the Principal Investigator.&#xD;
&#xD;
          -  Inability to fast for 8 hours prior to the initial blood draw&#xD;
&#xD;
          -  Immunization: Immunized with Pneumovax 23, or Immunized with Prevnar&#xD;
&#xD;
          -  Medications:Currently taking any of the following medications or within the 4 weeks of&#xD;
             study:&#xD;
&#xD;
             i. Immunosuppressive drugs or chemotherapeutic agents such as azathioprine,&#xD;
             mycophenolate mofetil, TNF inhibitors, cyclosporine, methotrexate, leflunomide,&#xD;
             cyclophosphamide, sulfasalazine, antimalarial drugs, chlorambucil, nitrogen mustard&#xD;
&#xD;
        ii. Steroids such as prednisone, cortisone, hydrocortisone&#xD;
&#xD;
        iii. Antidiabetic drugs such as metformin, insulin, glipizide, meglitinide, sulfonylurea,&#xD;
        glimepiride, repaglinide, nateglinide&#xD;
&#xD;
          -  History of clinical illness (exclusion during clinic)&#xD;
&#xD;
               1. Pneumonia or Previously had Pneumonia&#xD;
&#xD;
               2. Low blood pressure or Experienced dizzy spells&#xD;
&#xD;
               3. Significant cardiovascular disease:Recently hospitalizations deemed significant&#xD;
                  at the discretion of the Principal Investigator, or History of heart attack, or&#xD;
                  History of stroke&#xD;
&#xD;
               4. Spleen, Splenectomy, or Damage to spleen&#xD;
&#xD;
               5. Lung Disease or History of lung disease&#xD;
&#xD;
               6. Kidney disease, Blood in urine, or Protein in urine&#xD;
&#xD;
               7. Liver disease, Previous or current liver diseases such as hepatitis A, B, or C,&#xD;
                  liver cirrhosis, or autoimmune hepatitis, or Elevated AST/ALT lab test&#xD;
&#xD;
               8. Leukopenias&#xD;
&#xD;
               9. Hemoglobinopathies, History of sickle cell disease, or thalassemia&#xD;
&#xD;
              10. HIV/AIDS, or a history of HIV infection&#xD;
&#xD;
              11. Recreational IV drug use, or Intravenous drug injection predisposes users to&#xD;
                  infections, such as human immunodeficiency virus, that may alter the immune&#xD;
                  system and therefore affect the immunoglobulin response to Pneumovax23.&#xD;
&#xD;
              12. History of IV-drug use, or IV drug use is a risk factor for HIV infection, which&#xD;
                  may change the immune response to Pneumovax 23.&#xD;
&#xD;
              13. History of idiopathic thrombocytopenic purpura&#xD;
&#xD;
              14. History of chronic inflammatory diseases such as rheumatoid arthritis or chronic&#xD;
                  granulomatous disease&#xD;
&#xD;
              15. Autoimmune disease&#xD;
&#xD;
              16. Immunodeficiencies: neutropenia, common variable immune deficiency, Bruton's&#xD;
                  X-linked agammaglobulinemia; SCID; Selective IgA deficiency; Wiskott-Aldrich&#xD;
                  Syndrome; Ataxia Telangiectasia; DiGeorge Syndrome; Chronic Granulomatous&#xD;
                  Disease; Hyper IgE Syndrome; Complement deficiencies&#xD;
&#xD;
          -  Weight&#xD;
&#xD;
               1. Planning on losing weight within the time frame of the study&#xD;
&#xD;
               2. Have experienced excessive weight loss or gain within two months prior to the&#xD;
                  study&#xD;
&#xD;
               3. Planning to undergo liposuction, gastric bypass, stomach stapling, whipple&#xD;
                  procedure, or reconstructive surgery involving transplantation of adipose tissue&#xD;
                  within the study period&#xD;
&#xD;
               4. Bodybuilder or someone who takes part in excessive weight training&#xD;
&#xD;
          -  Allergy&#xD;
&#xD;
               1. Any severe side effects from vaccines&#xD;
&#xD;
               2. Allergic reaction to phenol&#xD;
&#xD;
          -  Medications/Supplementations&#xD;
&#xD;
               1. Taking any antioxidant supplements (EmergenC)&#xD;
&#xD;
               2. Unable to refrain from antioxidant supplements throughout the duration of the&#xD;
                  study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Brantly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of Medicine &amp; Chief, Division of Pulmonary, Critical Care &amp; Sleep Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uf Ctsi Crc</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Sebastian M, Hsiao CJ, Futch HS, Eisinger RS, Dumeny L, Patel S, Gobena M, Katikaneni DS, Cohen J, Carpenter AM, Spiryda L, Heldermon CD, Jin L, Brantly ML. Obesity and STING1 genotype associate with 23-valent pneumococcal vaccination efficacy. JCI Insight. 2020 May 7;5(9). pii: 136141. doi: 10.1172/jci.insight.136141.</citation>
    <PMID>32376795</PMID>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>June 10, 2015</study_first_submitted>
  <study_first_submitted_qc>June 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2015</study_first_posted>
  <results_first_submitted>April 21, 2020</results_first_submitted>
  <results_first_submitted_qc>November 5, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 1, 2020</results_first_posted>
  <last_update_submitted>November 5, 2020</last_update_submitted>
  <last_update_submitted_qc>November 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pneumovax23</keyword>
  <keyword>Obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 17, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT02471014/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 17, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT02471014/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>56 consented. 6 participants failed secondary screening during the first visit.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Obese Individuals</title>
          <description>Participants in this group will receive one 0.5mL Pneumovax23 intramuscular vaccine at baseline, four questionnaires administered at baseline, and one 50mL blood draw at baseline and one 50mL blood draw up to 6 weeks later.&#xD;
Pneumovax 23: All participants will receive a single 0.5 mL Pneumovax 23 intramuscular vaccine at baseline.&#xD;
Blood tests: All participants will have two 50 milliliter blood draws: at baseline and up to 6 weeks later.&#xD;
Questionnaires: All participants will answer the following questionnaires:&#xD;
UCLA Loneliness Scale Questionnaire will be used to measure a difference between the groups.&#xD;
Perceived Stress Scale-10 Questionnaire will be used to measure a difference between the groups.&#xD;
Interpersonal Support Evaluation List-12 will be used to measure a difference between the groups Life Orientation Test-Revised will be used to measure a difference between the groups.</description>
        </group>
        <group group_id="P2">
          <title>Normal Individuals</title>
          <description>Participants in this group will receive one 0.5mL Pneumovax23 intramuscular vaccine at baseline, four questionnaires administered at baseline, and one 50mL blood draw at baseline and one 50mL blood draw up to 6 weeks later.&#xD;
Pneumovax 23: All participants will receive a single 0.5 mL Pneumovax 23 intramuscular vaccine at baseline.&#xD;
Blood tests: All participants will have two 50 milliliter blood draws: at baseline and up to 6 weeks later.&#xD;
Questionnaires: All participants will answer the following questionnaires:&#xD;
UCLA Loneliness Scale Questionnaire will be used to measure a difference between the groups.&#xD;
Perceived Stress Scale-10 Questionnaire will be used to measure a difference between the groups.&#xD;
Interpersonal Support Evaluation List-12 will be used to measure a difference between the groups Life Orientation Test-Revised will be used to measure a difference between the groups.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The baseline population is the same.</population>
      <group_list>
        <group group_id="B1">
          <title>Obese Individuals</title>
          <description>Participants in this group will receive one 0.5mL Pneumovax23 intramuscular vaccine at baseline, four questionnaires administered at baseline, and one 50mL blood draw at baseline and one 50mL blood draw up to 6 weeks later.&#xD;
Pneumovax 23: All participants will receive a single 0.5 mL Pneumovax 23 intramuscular vaccine at baseline.&#xD;
Blood tests: All participants will have two 50 milliliter blood draws: at baseline and up to 6 weeks later.&#xD;
Questionnaires: All participants will answer the following questionnaires:&#xD;
UCLA Loneliness Scale Questionnaire will be used to measure a difference between the groups.&#xD;
Perceived Stress Scale-10 Questionnaire will be used to measure a difference between the groups.&#xD;
Interpersonal Support Evaluation List-12 will be used to measure a difference between the groups Life Orientation Test-Revised will be used to measure a difference between the groups.</description>
        </group>
        <group group_id="B2">
          <title>Normal Individuals</title>
          <description>Participants in this group will receive one 0.5mL Pneumovax23 intramuscular vaccine at baseline, four questionnaires administered at baseline, and one 50mL blood draw at baseline and one 50mL blood draw up to 6 weeks later.&#xD;
Pneumovax 23: All participants will receive a single 0.5 mL Pneumovax 23 intramuscular vaccine at baseline.&#xD;
Blood tests: All participants will have two 50 milliliter blood draws: at baseline and up to 6 weeks later.&#xD;
Questionnaires: All participants will answer the following questionnaires:&#xD;
UCLA Loneliness Scale Questionnaire will be used to measure a difference between the groups.&#xD;
Perceived Stress Scale-10 Questionnaire will be used to measure a difference between the groups.&#xD;
Interpersonal Support Evaluation List-12 will be used to measure a difference between the groups Life Orientation Test-Revised will be used to measure a difference between the groups.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="46"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.0" spread="5.32"/>
                    <measurement group_id="B2" value="23.0" spread="3.08"/>
                    <measurement group_id="B3" value="26.0" spread="5.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Anti-pneumococcal Antibodies Between the Groups</title>
        <description>IgG antibody titers specific for each serotype in Pneumovax 23 (i.e. 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F) will be analyzed.</description>
        <time_frame>Changes in baseline and up to 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Obese Individuals</title>
            <description>Participants in this group will receive one 0.5mL Pneumovax23 intramuscular vaccine at baseline, four questionnaires administered at baseline, and one 50mL blood draw at baseline and one 50mL blood draw up to 6 weeks later.&#xD;
Pneumovax 23: All participants will receive a single 0.5 mL Pneumovax 23 intramuscular vaccine at baseline.&#xD;
Blood tests: All participants will have two 50 milliliter blood draws: at baseline and up to 6 weeks later.&#xD;
Questionnaires: All participants will answer the following questionnaires:&#xD;
UCLA Loneliness Scale Questionnaire will be used to measure a difference between the groups.&#xD;
Perceived Stress Scale-10 Questionnaire will be used to measure a difference between the groups.&#xD;
Interpersonal Support Evaluation List-12 will be used to measure a difference between the groups Life Orientation Test-Revised will be used to measure a difference between the groups.</description>
          </group>
          <group group_id="O2">
            <title>Normal Individuals</title>
            <description>Participants in this group will receive one 0.5mL Pneumovax23 intramuscular vaccine at baseline, four questionnaires administered at baseline, and one 50mL blood draw at baseline and one 50mL blood draw up to 6 weeks later.&#xD;
Pneumovax 23: All participants will receive a single 0.5 mL Pneumovax 23 intramuscular vaccine at baseline.&#xD;
Blood tests: All participants will have two 50 milliliter blood draws: at baseline and up to 6 weeks later.&#xD;
Questionnaires: All participants will answer the following questionnaires:&#xD;
UCLA Loneliness Scale Questionnaire will be used to measure a difference between the groups.&#xD;
Perceived Stress Scale-10 Questionnaire will be used to measure a difference between the groups.&#xD;
Interpersonal Support Evaluation List-12 will be used to measure a difference between the groups Life Orientation Test-Revised will be used to measure a difference between the groups.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-pneumococcal Antibodies Between the Groups</title>
          <description>IgG antibody titers specific for each serotype in Pneumovax 23 (i.e. 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F) will be analyzed.</description>
          <units>titer</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.1" spread="3.51"/>
                    <measurement group_id="O2" value="19.8" spread="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>UCLA Loneliness Scale Questionnaire Will be Used to Measure a Difference Between the Groups.</title>
        <description>The UCLA loneliness scale is a 20-item questionnaire, on a scale of 0-3 for each question. This questionnaire measures subjective feelings of loneliness and social isolation. Final score of 0 reflects no loneliness and 60 reflects the maximum amount of loneliness.</description>
        <time_frame>Baseline</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Perceived Stress Scale-10 Questionnaire Will be Used to Measure a Difference Between the Groups.</title>
        <description>The Perceived Stress Scale-10 is a 10-item questionnaire assessing how stressful participants perceive their lives to be. Each question is assessed on a scale of 0 to 4. Final score of 0 reflects no stress and 40 indicates maximum amount of stress.</description>
        <time_frame>Baseline</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Interpersonal Support Evaluation List-12 Will be Used to Measure a Difference Between the Groups</title>
        <description>The Interpersonal Support Evaluation List-12, a 12-item questionnaire that measures perceived social support along 3 dimensions: appraisal support (availability of someone to talk to), belonging support (availability of people to do things with), and tangible support (e.g. material aid). This is measured on a scale of 0 to 36. The greater the number the greater perceived support.</description>
        <time_frame>Baseline</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Life Orientation Test-Revised Will be Used to Measure a Difference Between the Groups.</title>
        <description>The Life Orientation Test-Revised, a 10-item scale measuring optimism versus pessimism along a continuous scale; a higher score indicates more optimism. The lowest score is 0 and the highest is 24.</description>
        <time_frame>Baseline</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Genetic Analysis</title>
        <description>A small amount of blood will be sent to a research laboratory for an analysis of genetic markers Specifically, we will be analyzing the the stimulator of interferon genes (STING). This will help us determine if this gene, which has been previously thought to contribute to Pneumovax efficacy, helps explain individual differences in immune response.</description>
        <time_frame>Test to be performed in a research laboratory after Visits are completed</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4-6 weeks</time_frame>
      <desc>No subjects experienced serious adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Obese Individuals</title>
          <description>Participants in this group will receive one 0.5mL Pneumovax23 intramuscular vaccine at baseline, four questionnaires administered at baseline, and one 50mL blood draw at baseline and one 50mL blood draw up to 6 weeks later.&#xD;
Pneumovax 23: All participants will receive a single 0.5 mL Pneumovax 23 intramuscular vaccine at baseline.&#xD;
Blood tests: All participants will have two 50 milliliter blood draws: at baseline and up to 6 weeks later.&#xD;
Questionnaires: All participants will answer the following questionnaires:&#xD;
UCLA Loneliness Scale Questionnaire will be used to measure a difference between the groups.&#xD;
Perceived Stress Scale-10 Questionnaire will be used to measure a difference between the groups.&#xD;
Interpersonal Support Evaluation List-12 will be used to measure a difference between the groups Life Orientation Test-Revised will be used to measure a difference between the groups.</description>
        </group>
        <group group_id="E2">
          <title>Normal Individuals</title>
          <description>Participants in this group will receive one 0.5mL Pneumovax23 intramuscular vaccine at baseline, four questionnaires administered at baseline, and one 50mL blood draw at baseline and one 50mL blood draw up to 6 weeks later.&#xD;
Pneumovax 23: All participants will receive a single 0.5 mL Pneumovax 23 intramuscular vaccine at baseline.&#xD;
Blood tests: All participants will have two 50 milliliter blood draws: at baseline and up to 6 weeks later.&#xD;
Questionnaires: All participants will answer the following questionnaires:&#xD;
UCLA Loneliness Scale Questionnaire will be used to measure a difference between the groups.&#xD;
Perceived Stress Scale-10 Questionnaire will be used to measure a difference between the groups.&#xD;
Interpersonal Support Evaluation List-12 will be used to measure a difference between the groups Life Orientation Test-Revised will be used to measure a difference between the groups.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mathew Sebastian, PhD</name_or_title>
      <organization>University of Florida</organization>
      <phone>8644901978</phone>
      <email>mathewsebastian@ufl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

